EPIX News and Press, ESSA Pharma Inc. From 10/31/22

Canadian biotech ESSA Pharma ( NASDAQ: EPIX ) shed ~26% pre-market Monday after announcing that Janssen Research and Development of Johnson & Johnson ( JNJ ) will no longer enroll patients in a Phase 1 trial for a drug combination involving its lead asset EPI-7386 in...

ESSA Provides an Update on its Clinical Collaboration with Janssen Canada NewsWire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 31, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutica...

3 Mistakes That Beginner Penny Stock Traders Make Investing in penny stocks can be a great way to make money, but it can also be a quick way to lose money if you’re not careful. There are a few common mistakes that beginner penny stock investors make that can cost them dearly...

3 Strategies for Making Money With Penny Stocks Right Now While there are certainly risks involved with investing in penny stocks, there are also a number of strategies that investors can use to try to make money with them. By doing your research and being aware of the risks, you may be...

ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium Canada NewsWire SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 26, 2022 /CNW/ - ESSA Pharma ...

Canadian biotech ESSA Pharma Inc. ( NASDAQ: EPIX ) added 91% in the morning hours Wednesday after announcing Phase 1/2 data for a prostate cancer therapy combining its lead asset EPI-7386 with enzalutamide developed by Pfizer ( PFE ) and Astellas Pharma ( OTCPK:ALPMF...

Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat Canada NewsWire EPI-7386 in combination with enzalutamide was safe and well-tolerate...

ESSA Pharma Appoints Philip Kantoff to its Board of Directors PR Newswire SOUTH SAN FRANCISCO , California and VANCOUVER, Canada , Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pha...

Summary Shares of early-stage prostate cancer concern ESSA Pharma Inc. are down 90% since May 2021 as trial data delays and vague messaging suggest that its therapy is running into issues about effectiveness and the market size for its therapy. It does not help that management has...

ESSA Pharma press release ( NASDAQ: EPIX ): FQ3 GAAP EPS of -$0.20 (vs. -$0.21 Y/Y). At June 30, 2022, the Company had available cash reserves and short-term investments of $174.6 million. For further details see: ESSA Pharma GAAP EPS of -$0.20